202 related articles for article (PubMed ID: 23438963)
1. The complementary roles of imaging and 'omics' for future anti-atherosclerotic drug development.
Puri R; Nissen SE
Curr Pharm Des; 2013; 19(33):5963-71. PubMed ID: 23438963
[TBL] [Abstract][Full Text] [Related]
2. Emerging applications of metabolomics in drug discovery and precision medicine.
Wishart DS
Nat Rev Drug Discov; 2016 Jul; 15(7):473-84. PubMed ID: 26965202
[TBL] [Abstract][Full Text] [Related]
3. Clinical imaging in anti-atherosclerosis drug development.
Ehlgen A; Bylock A; Kreuzer J; Koslowski M; Gantner F; Niessen HG
Drug Discov Today; 2015 Nov; 20(11):1317-27. PubMed ID: 26151479
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of lipidomics.
Stock J
Atherosclerosis; 2012 Mar; 221(1):38-40. PubMed ID: 22178427
[No Abstract] [Full Text] [Related]
5. Form to function: current and future roles for atherosclerosis imaging in drug development.
Lindsay AC; Choudhury RP
Nat Rev Drug Discov; 2008 Jun; 7(6):517-29. PubMed ID: 18483481
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound carotid artery intima-media thickness assessment for progression of atherosclerosis in lipid intervention studies.
Naqvi TZ
Curr Opin Investig Drugs; 2008 Mar; 9(3):256-64. PubMed ID: 18311661
[TBL] [Abstract][Full Text] [Related]
7. Atherosclerosis imaging in progression/regression trials: surrogate marker or direct window into the atherosclerotic disease process?
Schoenhagen P; Tuzcu EM
Arq Bras Cardiol; 2008 Dec; 91(6):385-98. PubMed ID: 19142366
[TBL] [Abstract][Full Text] [Related]
8. Precision phenotyping, panomics, and system-level bioinformatics to delineate complex biologies of atherosclerosis: rationale and design of the "Genetic Loci and the Burden of Atherosclerotic Lesions" study.
Voros S; Maurovich-Horvat P; Marvasty IB; Bansal AT; Barnes MR; Vazquez G; Murray SS; Voros V; Merkely B; Brown BO; Warnick GR
J Cardiovasc Comput Tomogr; 2014; 8(6):442-51. PubMed ID: 25439791
[TBL] [Abstract][Full Text] [Related]
9. Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate.
Nanchen D; Raggi P
Atherosclerosis; 2017 Nov; 266():229-233. PubMed ID: 28882315
[TBL] [Abstract][Full Text] [Related]
10. Intravascular ultrasound for the evaluation of therapies targeting coronary atherosclerosis.
Böse D; von Birgelen C; Erbel R
J Am Coll Cardiol; 2007 Mar; 49(9):925-32. PubMed ID: 17336714
[TBL] [Abstract][Full Text] [Related]
11. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
Nelson JR; Wani O; May HT; Budoff M
Vascul Pharmacol; 2017 Apr; 91():1-9. PubMed ID: 28263852
[TBL] [Abstract][Full Text] [Related]
12. Blood atherogenicity as a target for anti-atherosclerotic therapy.
Sobenin IA; Chistiakov DA; Bobryshev YV; Orekhov AN
Curr Pharm Des; 2013; 19(33):5954-62. PubMed ID: 23438956
[TBL] [Abstract][Full Text] [Related]
13. Advances in the role of microRNAs in lipid metabolism-related anti-atherosclerotic drug discovery.
Wang L; Yang Y; Hong B
Expert Opin Drug Discov; 2013 Aug; 8(8):977-90. PubMed ID: 23668290
[TBL] [Abstract][Full Text] [Related]
14. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
Hodis HN
J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive atherosclerosis imaging: use to assess response to novel or combination lipid therapies.
Villines TC; Taylor AJ
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):557-64. PubMed ID: 16503876
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future.
Weber C; Badimon L; Mach F; van der Vorst EPC
Thromb Haemost; 2017 Jun; 117(7):1258-1264. PubMed ID: 28594053
[TBL] [Abstract][Full Text] [Related]
17. Plaque imaging to refine indications for emerging lipid-lowering drugs.
Alkhalil M; Chai JT; Choudhury RP
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):58-67. PubMed ID: 27816944
[TBL] [Abstract][Full Text] [Related]
18. Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases.
Dang VT; Huang A; Werstuck GH
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):166-175. PubMed ID: 29683098
[TBL] [Abstract][Full Text] [Related]
19. Applications of metabolomics in drug discovery and development.
Wishart DS
Drugs R D; 2008; 9(5):307-22. PubMed ID: 18721000
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
